AMGN - Amgen - Stock Forecast

Healthcare - Sector
Coverage Profile Stock analysts Price Targets & Ratings Chart Insider Trading

AMGN is currently covered by 23 analysts with an average price target of $336.25. This is a potential upside of $26.84 (8.67%) from yesterday's end of day stock price of $309.41.

Amgen's activity chart (see below) currently has 445 price targets and 389 ratings on display. The stock rating distribution of AMGN is 36.96% HOLD, 50% BUY and 13.04% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 91.84% with an average time for these price targets to be met of 541.9 days.

Highest price target for AMGN is $355, Lowest price target is $200, average price target is $336.25.

Most recent stock forecast was given by SALIM SYED from MIZUHO on 09-May-2024.

What is Amgen?

Amgen is a biotechnology company that specializes in  developing, manufacturing, and delivering human therapeutics.

The company’s research focuses on six main therapeutic areas, which include inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience.

Products

Amgen produces drugs such as Enbrel, Neulasta, Prolia, Xgeva, Aranesp, KYPROLIS, and Repatha, which treat anemia, cardiovascular disease, multiple myeloma, osteoporosis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis.

  • Enbrel
    • Treats inflammatory conditions such as plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis. A healthcare provider or the patient injects Enbrel to inhibit tumor necrosis factor (TNF).
  • Neulasta
    • This product reduces the risk of infection in cancer patients undergoing chemotherapy, by stimulating the bone marrow to produce more white blood cells. It is administered by injection, usually 24 hours after chemotherapy.
  • Prolia
    • Treats postmenopausal women with osteoporosis by inhibiting RANKL, a protein involved in bone tissue breakdown. It is given by injection every six months. Prolia can increase bone density and reduce fractures.

History

Amgen was founded in 1980 and is headquartered in Thousand Oaks, California.

Currently out of the existing stock ratings of AMGN, 34 are a HOLD (36.96%), 46 are a BUY (50%), 12 are a SELL (13.04%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

235

$-79.85 (-25.36%)

223

13 days ago

15/20 (75%)

$-77.86 (-24.89%)

388

Sell

300

$-14.85 (-4.72%)

230

19 days ago

17/19 (89.47%)

$-11.29 (-3.63%)

223

Hold

307

$-7.85 (-2.49%)

284

19 days ago

10/10 (100%)

$-4.29 (-1.38%)

79

Buy

328

$13.15 (4.18%)

329

19 days ago

6/9 (66.67%)

$16.71 (5.37%)

68

Buy

355

$40.15 (12.75%)

326

19 days ago

17/19 (89.47%)

$43.71 (14.04%)

439

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is AMGN (Amgen) average time for price targets to be met?

On average it took 541.9 days on average for the stock forecasts to be realized with a an average price target met ratio 91.84

Which analyst has the current highest performing score on AMGN (Amgen) with a proven track record?

DO KIM

Which analyst has the most public recommendations on AMGN (Amgen)?

Do Kim has 44 price targets and 26 ratings on AMGN

Which analyst is the currently most bullish on AMGN (Amgen)?

Evan Seigerman with highest potential upside - $40.15

Which analyst is the currently most reserved on AMGN (Amgen)?

Matthew Roden with lowest potential downside - -$146.85

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?